A Phase II study of Trabectedin in patients with advanced mesenchymal chondrosarcoma with genetic rearrangement.
Contact Information for Access
Status
ATTIVO
Objective of the study
To evaluate the efficacy of trabectedin in the 2nd to 4th lines of treatment for patients with advanced HEY1-NOCA2-positive MCS who have previously received anthracycline-based chemotherapy.
Non-conventional chondrosarcoma.
ClinicalTrials.gov ID NCT04305548
Sponsor: Italian Sarcoma Group
Medication
Trabectedin
Who is eligible to participate in the study?
Patients who are 18 years of age or older and who meet the study’s eligibility criteria may participate in this study.
Patients who have received at least one prior treatment.
View the full study Back to search page